FDAnews
www.fdanews.com/articles/123787-tekmira-makes-improvements-in-the-potency-of-rnai-delivery-platform

Tekmira Makes Improvements in the Potency of RNAi Delivery Platform

January 19, 2010
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics and proprietary delivery technology, announced Tuesday that new research published in the journal Nature Biotechnology discloses the development of a new lipid component that provides a ten-fold improvement in the potency of the Company’s SNALP delivery platform.
Earth Times